| Japanese |
|---|
| Title | 169Yb - citrateの腫瘍への取り込み |
|---|
| Subtitle | 原著 |
|---|
| Authors | 東与光*, 藤村忠士*, 中山義之**, 久田太郎***, 戸村健児○, 川井邦男○○, 中村功○○○ |
|---|
| Authors(kana) | |
|---|
| Organization | *神奈川歯科大学放射線学教室, **生化学教室, ***病理学教室, ○立教大学原子力研究所, ○○東京薬科大学, ○○○横浜警友病院 |
|---|
| Journal | 核医学 |
|---|
| Volume | 10 |
|---|
| Number | 1 |
|---|
| Page | 27-35 |
|---|
| Year/Month | 1973/2 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「1. はじめに」最近, 放射性の希土類元素である169Yb, 157Dy, 153Smなどの核種が医療用にも使用されるようになった. 私たちも周期律表のIIIa族であるランタノイド系の希土類元素に着目して, これらの核種について動物腫瘍への取り込みと体内分布をしらべ, その概要をさきに報告した. 同じようなこころみで久田, 安東らも報告している. 現在, わが国で希土類元素のうち医療用に使用されている核種は脳室シンチグラム用の169Yb-DTPAである. 久田, 安東らは169Yb-citrateの腫瘍親和性について報告している. 私たちも169Ybについて動物腫瘍への取り込みと代謝をしらべた. また, 少ない症例であるが臨床にも169Yb-citrateをこころみたので, その結果を報告する. 「2. 動物実験」「(1)169Ybの排泄」使用動物は成熟雄マウス(DDN系)の大腿部にエールリッヒ腹水癌を移植して, 10日目の担癌マウスを用いた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | |
|---|
| English |
|---|
| Title | On the Accumulation of 169Yb - citrate in Malignant Tumor |
|---|
| Subtitle | Original |
|---|
| Authors | Tomomitu HIGASI*, Tadashi FUJIMURA*, Yoshiyuki NAKAYAMA**, Taro HISADA***, Kenji TOMURA*, Kunio KAWAI**, Ko NAKAMURA |
|---|
| Authors(kana) | |
|---|
| Organization | Kanagawa Dental College *Department of Radiology, **Department of Biochemistry, ***Department of Pathology, *Institute for Atomic Energy of Rikkyo University, **Tokyo College of Pharmacy, Yokohama Keiyu Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 10 |
|---|
| Number | 1 |
|---|
| Page | 27-35 |
|---|
| Year/Month | 1973/2 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [ABSTRACT]Numerous recent reports have indicated that 67Ga-citrate is readily taken up by malignant tissues. Since then many investigators have tried to find a better tumor-specific scanning agent than 67Ga-citrate for the diagnosis of malignant tumors, However, as yes, success has been limited. Recently, radioactive rare earch elements such as 169Yb, 153Sm and 157Dy have been introduced to nuclear medicine. The authors studied the uptake of 169Yb-citrate by Ehrlich's tumor-bearing mice and Yoshida sarcoma-bearing rats. The excretion following intraperitoneal injection of 169YbCl3 and 169Yb-citrate was examined. Figures 1 and 2 show the excretion curves of 169YbCl3 and 169Yb-citrate respectively. The excretion of 169Yb-citrate was significantly and consistetly greater than that of 169YbCl3. When the 169Yb-citrate containing carrier dose of 0.5mg stable YbCl3 was injected in Ehrlich's tumor-bearing mice, the excretion of the 169Yb-citrate was greatly decreased. In addition, when the 169Yb-citrate containing carrier dose of 0.5mg stable CaCl2 was injected in Ehrlich's tumor-bearing mice, the excretion of the 169Yb-citrate was somewhat decreased. Scintigrams taken 48hours after the administration of 150μCi of 169Yb-citrate in Yoshida sarcoma-bearing rats showed high uptake in bone and in tumor. Wholebody autoradiogram taken 48 hours after the administration of 100μCi of 169Yb-citrate in Ehrlich's tumor-bearing mice showed high uptake in bone but the uptake in other organs was poor. Furthermore, 169Yb-citrate was obviously taken up by the active inflammatory lesions in the femoral legion of rats as well as the tumor tissue. A comparison of the accumulation of 169Yb-citrate with the accumulation of 67Ga-citrate in the Ehrlich's tumor-bearing mice was performed. It was found that 67Ga-citrate was better incorporated in 35 Ehrlich's tumor than 169Yb-citrate. Clinically, because 169Yb-citrate strongly accumulates in the vertebra as well as in tumor tissue, it is impossible to diagnose cancerous lesions of the mediastinum. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | |
|---|